Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| There are additional benefits to the clinic that offer the convenience of point of prescription medication dispensing, such as improved quality ratings associated with medication compliance and increased patient satisfaction that can drive potential incremental reimbursement revenue |
| This not only positively impacts our current expense run rate but should also create a better experience for our partners |
| During the first quarter, we continued to make excellent progress executing on our mission to become a leading pharmacy technology company following our announcement in January that we were divesting the SpotRx Pharmacy Services business which we subsequently sold to CVS during the quarter |
| I will say that with Oak Street, we had a very strong partnership |
| And while it is still early, our leading indicators suggest that our strategy is working, as evidenced in part by our robust and growing pipeline, which is comprised of both existing and new partners that I will discuss in more detail shortly |
| Again, we are in the very early stages of tapping into the numerous significant and long term growth opportunities that we have identified for the pharmacy technology business and we are excited about what we can achieve this year in terms of laying a foundation for future growth and profitability |
| I also believe we are on the right track to be a leader in the field of pharmacy kiosk dispensing to the benefit of both clinics and patients while creating enduring value for our shareholders |
| I am very pleased with the significant progress we have made in the relatively short time since we announced the sale of SpotRx to CVS in January |
| Our early progress is very encouraging and gives me confidence that we have placed MedAvail on a path to success |
| We continue to anticipate a gross margin in excess of 60% for the full year, which would represent a significant improvement from our full year 2022 gross margin of 47% |
| We further assume a full year gross margin in excess of 60%, well above 45%, which represents a fully costed margin at current volumes and representing nice expansion relative to our pharmacy technology gross margin of 47% as we reported for full year 2022 |
| Over the long term, we view this as a significant opportunity to work with state lawmakers to continue to expand our serviceable market which currently stands at more than $1.3 billion with an additional $500 million in recurring software license and maintenance revenue |
| By doing so, prescription abandonment rates can be reduced and this can inherently lead to improved patient outcomes |
| Our successful integration with the Epic Willow Pharmacy Management System is providing a significant tailwind for us and is resonating with many primary care and urgent care clinics across the US who utilize that system |
| We continue to see growing demand for the MedCenter among both existing and new partners across our current primary care and urgent care chains |
| Further, we anticipate that a combination of higher revenue and margin together with lower expenses will reduce our quarterly cash burn, excluding SpotRx throughout the balance of this year |
| The MedCenter is designed to provide patients with enhanced quality and safety through its integrated barcode technology and convenience with expeditious dispensing times that average 5 to 7 minutes while offering access to a live pharmacist when needed |
| In all, based on the current contracting momentum that we are seeing, as I stated previously, we are confident with our guidance of 25 net new dispensing MedCenters in place during 2023, bringing our total network to 57 cumulative dispensing MedCenters by December 31 |
| With the wind down of SpotRx well underway, we have continued to look for opportunities within the core pharmacy technology business to manage our expenses carefully and become more nimble and efficient |
| This will further reduce cost and accelerate MedCenter deployments |
| Total company adjusted EBITDA for the first quarter was a loss of $3.7 million, representing a 15.9% improvement from $4.4 million loss in the first quarter 2022 |
| The ability to remotely dispense 600 to 1,000 medications in roughly 13 square feet is a cost-effective way to bring pharmacy to the point of care and it's like having a pharmacy in a box |
| And again, there's a predominant number of states that have favorable regulations or waiver processes in them such that we believe we can cover about 72% of the population |
| And so we think that's going to help us build out those integrations in an efficient manner |
| We are committed to operating a lean organization capable of responding quickly to new growth opportunities as they emerge |
| With the MedCenter, we bring prescription medication dispensing to the point of care through our innovative hardware and software platforms |
| And the Encora partnership should facilitate faster completion of full integrations with these systems |
| MedAvail is able to complete a proof-of-concept integration in six to eight weeks for partners that want to accelerate deployment of the MedCenter |
| We believe there will be others as additional states embrace the many advantages, kiosk dispensing to both the clinic and patient |
| For the first quarter of 2023, we generated total revenue of approximately $620,000, representing growth of 134% and over Pharmacy Technology revenue in the comparable period in 2022 of $265,000 and growth of 143% over fourth quarter 2022 Pharmacy Technology revenue of $255,000 |
| Statement |
|---|
| This pharmacy labor shortage has been persistent and has not been improving |
| Additionally, pharmacies are currently suffering a shortage of both pharmacists and pharmacy technicians, which is resulting in restricted or delayed patient access to medication |
| This was another difficult but required action that further reduced our overall headcount by approximately 27% |
| We also terminated our agreement with our kiosk manufacturer, Kitron, given the more than 100 prebuilt MedCenters that we currently have in inventory |
| Total Pharmacy Technology operating expenses for the first quarter 2023 were $5.3 million down from $5.5 million in the first quarter of 2022 |
| Despite these positive developments, half of the states continue to be restricted or have rules in place that we consider to be unfavorable |
| We anticipate being substantially done by the end of the second quarter and the majority of expenses associated with the closure, which have been lower than projected, are expected to be captured in the second quarter as well |
| Given the many benefits of remote dispensing to both patient and the clinic that I previously touched on and the worsening shortage of pharmacists and pharmacy techs, we anticipate that the regulatory environment will continue to evolve in our favor |
| To that end, we conducted an additional reduction in force at the end of April, mostly impacting our development, quality assurance teams |
Please consider a small donation if you think this website provides you with relevant information